Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 605 participants.
Also called NCT03895502
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 605 participants
- Sponsor
- Registry
-
NCT03895502
-
- Other papers using this trial's data
- Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial
- Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT03895502. Randomized; no masking; primary purpose treatment. Start 2019-05-27 (actual); primary completion 2023-06-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimal Duration of Anticoagulation Therapy for Isolated Distal Deep Vein Thrombosis in Patients With Cancer Study
- Acronym
- ONCO DVT
- Condition
- Venous Thrombosis
- Condition
- Neoplasms
- Condition
- Anticoagulant
- Intervention (Drug)
- 12-month Edoxaban
- Intervention (Drug)
- 3-month Edoxaban
- Lead sponsor
- Takeshi Morimoto
Record details
- Record id
cardio:ct-nct03895502- Content hash
dac19df87ca71e7006d26fc5dad209b8911a89acb0ce65d522fac9f2a2d34245